Winston Pharmaceuticals, Inc. ("Winston"), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant under the Small Business Innovation Research (SBIR) program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately $375,000 will be administered by the National Institute of Neurological Disorders and Stroke (NINDS).
“We are extremely pleased by the award of this SBIR grant”
"We are extremely pleased by the award of this SBIR grant," said Joel E. Bernstein, M.D., President and CEO of Winston. "The development of civamide nasal solution for treatment of PHN of the trigeminal nerve could bring relief to many patients suffering with this severe chronic pain. The use of TRPV-1 modulators in treating neuropathic disease is a unique approach in this area, and this SBIR grant gives us an opportunity to further investigate the use of this class of medications. The availability of an effective and safe treatment, i.e., without systemic effects or drug interactions, would fill an important unmet medical need in the treatment of PHN of the TN."